<DOC>
	<DOCNO>NCT00706797</DOCNO>
	<brief_summary>To assess comparative radiographic efficacy , clinical efficacy safety etanercept ( ETN ) + methotrexate ( MTX ) usual disease-modifying anti-rheumatic drug ( DMARD ) treatment subject moderate RA treat MTX monotherapy , continue moderate disease activity .</brief_summary>
	<brief_title>Study Evaluating Efficacy / Safety Etanercept + Methotrexate Compared Usual Treatment Moderate RA Subjects</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Meet 1987 ACR Revised Criteria Rheumatoid Arthritis . Documented evidence , confirm blind 3rd party assessor , least one erosion observe Xray randomization base Xray take screen visit . Have receive MTX stable dose 28 day prior screen visit . Previous treatment ETN , infliximab , adalimumab , Tumor necrosis factor ( TNF ) inhibitor , anakinra biological agent . Receipt DMARD , MTX , within 28 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Moderate Rheumatoid Arthritis</keyword>
</DOC>